|List [record 1 of 1]|
|Coordinate||103,249,558 bp (GRCm38)|
|Base Change||G ⇒ A (forward strand)|
|Gene Name||mitogen-activated protein kinase kinase kinase 14|
|Chromosomal Location||103,219,762-103,267,472 bp (-)|
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] This gene encodes mitogen-activated protein kinase kinase kinase 14, which is a serine/threonine protein-kinase. This kinase binds to TRAF2 and stimulates NF-kappaB activity. It shares sequence similarity with several other MAPKK kinases. It participates in an NF-kappaB-inducing signalling cascade common to receptors of the tumour-necrosis/nerve-growth factor (TNF/NGF) family and to the interleukin-1 type-I receptor. [provided by RefSeq, Jul 2008]
PHENOTYPE: Homozygotes for a spontaneous mutation exhibit deficiencies in cellular and humoral immunity, susceptibility to infections, absence of lymph nodes and Peyer's patches, failure of isotype switching, and inflammation of exocrine organs. [provided by MGI curators]
|Amino Acid Change||Arginine changed to Stop codon|
|Institutional Source||Beutler Lab|
R396* in Ensembl: ENSMUSP00000021324 (fasta)
|Gene Model||not available|
|Alleles Listed at MGI|
|Mode of Inheritance||Autosomal Recessive|
|Local Stock||Sperm, gDNA|
|Last Updated||2017-04-06 1:01 PM by Katherine Timer|
Lucky mice were identified in a T-dependent humoral response screen for mutations that abrogate the humoral immune response to model antigens encoded by a recombinant suicide vector based on the Semliki Forest Virus (rSFV). ENU-mutagenized G3 mice, along with wild type controls, were injected intraperitoneally with 2x106 infectious units (IU) of rSFV encoding the model antigen, beta-galactosidase (rSFV-GAL). Two weeks later, the mice were boosted with the same dose of rSFV-GAL. On day 28, serum levels of GAL-specific IgG were measured. The index mouse, B6004, failed to produce a detectable GAL-specific IgG response (Figure 1).
Flow cytometric analysis of peripheral blood lymphocytes revealed that the index mouse and two additional G3 siblings had a significant reduction of peripheral B cells. The B cells that were present in the blood of these mice expressed high levels of surface IgM and lacked surface expression of CD23 and CD21/CD35 (Figure 1). This surface phenotype is consistent with a block in B cell development from the transitional T1 stage to the T2 stage [for a review of B cell development see (1)]. This step in B cell development is an important checkpoint for deleting autoreactive B cells before they acquire the ability to enter lymphoid follicles and complete their development into mature B cells.
Further phenotypic analysis of homozygous lucky animals revealed a lack of secondary lymphoid organs.
|Nature of Mutation|
The lucky mutation was mapped to Chromosome 11, and corresponds to a C to T transversion at position 1269 of the Map3k14 gene in exon 6 of 16 total exons.
The mutated nucleotide is indicated in red lettering, and causes an arginine to stop conversion at amino acid 396 of the MAP3K14 protein.
The protein encoded by the Map3k14 gene is known as the NF-κB inducing kinase (NIK) (2). In mice, this protein is 942 amino acids long and has 84% identity with its human homologue (Figure 2) (3). NIK is a serine/threonine kinase belonging to the mitogen-activated protein kinase kinase kinase (MAP3K) family of proteins. The kinase domain of NIK spans amino acids 367-580 (3), and like other kinase domains contains motifs critical for ATP binding, substrate binding and catalysis (4). These include a conserved ATP-binding lysine, a glycine-rich loop also involved in ATP binding and phosphoryl transfer (amino acids 408-416), the magnesium-binding loop or subdomain VII, the activation loop, and subdomain VIII. Mutation of the ATP-binding lysine (amino acid 431) and an adjacent lysine (amino acid 432), abolishes NIK kinase activity (2). Activation of most protein kinases also requires phosphorylation of a residue in the activation loop. In NIK, this residue is T559. NIK can also form oligomers through multiple regions of its kinase domain (5).
The NIK N-terminal region also contains a negative-regulatory domain (NRD) in its N-terminus (amino acids 121-321) that interacts with the NIK C-terminal region, thus inhibiting binding to IKK-1. The NRD consists of a basic motif (amino acids 127-146) that is similar to the basic region of basic leucine zipper (bZIP) motifs present in some transcription factors, as well as a proline-rich repeat motif located between amino acids 250 and 320. The latter region is composed of five short repeats, which share the consensus sequence PXPXPX (23).
NIK contains a conventional nuclear localization signal (NLS) at amino acids 143-149 (2;24), which partially overlaps with the NRD basic motif. Typically, this signal consists of one or more short sequences of positively charged lysines or argines. The NLS contains a nucleolar sub-motif at amino acids 143-146 (25). A nuclear export signal (NES), consisting of short stretches of hydrophobic residues such as leucine or isoleucine, is located in the NIK C-terminus at amino acids 790-800 (24).
The lucky mutation results in the generation of a stop codon at amino acid 396, thus truncating the protein close to the N-terminus of its kinase domain. It is unknown whether the truncated protein is normally expressed.
NIK mRNA has been reported to be ubiquitously expressed at low levels in mouse and human tissues (2;26). NIK expression levels are also low in most cell types (27), but high levels of NIK are expressed in melanoma cell lines (16). According to SymAtlas, several tissues and cell types express higher levels of NIK mRNA. B cells express high levels of NIK mRNA in humans, while lymph nodes, spleen, and follicular B cells express high levels of NIK mRNA in mice.
Subcellularly, NIK protein is predominantly localized to the cytoplasm in cell lines and unstimulated macrophages (24;28). In endotoxin treated macrophages, NIK translocates to the nucleus (28), and NIK undergoes nucleocytoplasmic shuttling (24). NIK has also been shown to localize to the nucleolus (25).
The NF-κB signaling pathway functions in essentially all mammalian cell types and is activated in response to injury, infection, inflammation and other stressful conditions requiring rapid reprogramming of gene expression (Figure 3). The NF-κB family of transcription factors consists of the evolutionary conserved proteins p65/RelA, c-Rel, RelB, p50 (derived from the p105 precursor) and p52 (derived from the p100 precursor; see the record for xander). Typically, the rapid and transient activation of NF-κB complexes in response to a wide range of stimuli such as proinflammatory cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and CD40L (see the record for walla), DNA damaging agents, Toll-like receptor (TLR) agonists or viruses is regulated by the canonical NF-κB pathway. In the resting cell, NF-κB dimers are kept inactive in the cytoplasm through their association with IκB inhibitory molecules, including p105 and p100. In response to stimulation, IκBs are phosphorylated by the IκB kinase (IKK) complex, composed of IKK-1 (or IKK-α), IKK-2 (or IKK-β) and IKK-γ, at conserved serine residues (please see the record for panr2). This modification induces the K48-linked polyubiquitination of IκB molecules and subsequent recognition by the 26S proteasome as substrates for proteolysis. Degradation of IκBs allows the NF-κB dimers to translocate into the nucleus, where they are able to activate the transcription of target genes, including various cytokines [for review see (27)].
Some of the inducers of the canonical NF-κB pathway are also able to trigger an additional pathway by activating NIK and IKK-1 (27), known as the non-canonical or non-canonical NF-κB pathway. This pathway drives the post-translational processing of p100 to mature p52 (29), and appears to be mostly restricted to a subset of tumor necrosis factor (TNF) receptors including lymphotoxin-β receptor (LTβR), B cell activating receptor (BAFFR), CD40, and receptor activator of NF-κB (RANK) (8;30-35). These receptors are involved in secondary lymphoid organ (SLO) development, B cell differentiation, survival and homeostasis, and in osteoclastogenesis (27), and bind to TRAF proteins to regulate NIK activity. TRAF2 and TRAF5 positively regulate NIK activity under certain conditions (2;17), but in other contexts, TRAF2 and TRAF3 form a complex with NIK to mediate NIK degradation (18;36-38). After stimulation with BAFFR/CD40, the complex is destabilized by TRAF2/3 degradation, permitting the release of NIK from the complex (36-38). The TRAFs and NIK-associated protein (TNAP) may also play a role as it interacts with TRAF2, TRAF3 and NIK, and can suppress NIK activity (20). Once NIK is activated, it is able to bind to and phosphorylate several substrates including IKK-1 and p100, and serves as a docking molecule between IKK-1 and p100 (8;39;40). Once p100 is phosphorylated by IKK-1, it is polyubiquitinated and processed to p52 (40;41). The non-canonical NF-κB pathway is generally slower than the activation of the canonical pathway, leading to delayed activation of nuclear p52-containing complexes such as p52/RelB. p52 also pairs with p65 (RelA) and c-Rel, but these complexes are controlled by IκB molecules, and are downstream of both the canonical and non-canonical NF-κB pathways (27).
Alymphoplasia (aly) mice, which are homozygous for a point mutation in Map3k14 (3), exhibit deficiencies in cellular and humoral immunity, susceptibility to infections, absence of SLOs, defects in thymic and splenic architecture, abnormal B cell development, failure of isotype switching, and inflammation of exocrine organs (42-46). In addition, these animals have mammary gland defects (47), and demonstrate progressive neurological abnormalities leading to hind-limb paralysis (42). A targeted knockout of Map3k14 produced animals with very similar phenotypes (9). The phenotypes of animals with Map3k14 mutations resemble some of those found in Nfκb2 knockout mice lacking the p100 and p52 proteins (48;49), RelB-deficient mice (50;51), IKK-1-deficient animals (52;53), Ltβr knockouts (54), BAFFR-deficient mice (55;56), and RANK mutants (57;58). These mouse models have clarified the role of the non-canonical NF-κB pathway in several critical biological processes.
One of the most striking phenotypes of Map3k14 mutants is the lack or disturbance of SLO development, including lymph nodes (LNs), Peyer’s Patches (PPs) and spleen. SLOs provide an environment that enables lymphocytes to interact with each other, with accessory cells, and with antigens, resulting in the initiation of antigen-specific primary immune responses. All SLOs contain specific B cell and T cell areas, through which lymphocytes continuously recirculate, and are able to interact with antigen-presenting cells (APCs). In these tissues, immunization results in the appearance of germinal centers (GCs) that are sites of intense B cell proliferation, selection, maturation and death during antibody responses. The development of lymphoid tissues involves the interaction between hematopoietic progenitor cells and mesenchymal progenitor cells. This interaction is dependent on LTβR signaling through NIK and IKK-1 to activate the p52/RelB dimer, although canonical NF-κB signaling also plays a role and some functional redundancy exists (27). RANK-deficient mice also exhibit a lack of LNs although other SLO development is normal (57;58), suggesting a specific role for RANK in LN development. The same signaling pathway is important for the maturation, but not the initiation of PP development (27), and is critical for the formation of GCs in the spleen (48;59-61).
The non-canonical NF-κB pathway is also involved in thymic organogenesis and self-tolerance. The development and organization of the thymus are the result of interactions between maturing thymocytes and epithelial and dendritic cells (DCs). Subsets of thymic epithelial cells (TECs) require the non-canonical NF-κB pathway for proper development and maturation, and mutations in Ltβr, Map3k14, and Ikkα all disturb thymic architecture (42;62;63). LTβR-deficient mice exhibit thymic defects that are less severe than those found in alymphoplasia animals, suggesting that additional signals induce the non-canonical NF-κB pathway during thymic development (62).
In addition to their general defects in SLO and thymic differentiation, mice with Map3k14 mutations also display phenotypes intrinsic to specific immune cell populations (27). The non-canonical NF-κB pathway is important in B cell maturation and homeostasis (1;32), DC proliferation and differentiation (64-66), and Th17 development (67). NIK and IKK-1 appear to be dispensable for early B cell development in the bone marrow, but further maturation in the spleen to mature follicular B cells and non-circulating marginal zone B (MZB) cells is affected in Map3k14, Ikk-α, and Nfkb2 mutant animals (1;48;49;60;68). This process was shown to be largely dependent on signaling through BAFFR, which was also shown to be important for B cell maintenance (32). CD40, which has roles in B cell function and homeostasis, may also function upstream of NIK in B cells (69). Alymphoplasia dendritic cells (DCs) are reduced in number in the peripheral lymphoid organs, and have a reduced ability to induce both regulatory T (Treg) cell proliferation and to present antigens to cytotoxic T cells (64-66). Both CD40 and LTβR induction of the non-canonical NF-κB pathway were shown to be important for DC proliferation and differentiation (65;66). These DC defects result in a reduction of peripheral Tregs in alymphoplasia mice. As Tregs are necessary to maintain immunological tolerance by suppressing autoreactive T cells and shutting down T-cell mediated immunity, it is likely the autoimmune inflammations observed in the exocrine organs of alymphoplasia mice are due to the reduction in Treg cell number (45;64)
Besides NF-κB activation, IKK-1 activity was shown to be critical for type I interferon (IFN) production by activating interferon factor (IRF) 7 downstream of TLR7 or TLR9 (70). Type I IFNs are a critical class of cytokines that have potent antiviral, growth-inhibitory and immunomodulatory functions, and are transcriptionally controlled by activated IRF3 or IRF7 [for review see (71)]. The regulation of type I IFN by IKK-1 may be independent of NIK function as splenic cells from alymphoplasia mice produced normal amounts of TLR7 or TLR9-induced IFN-α (70). However, other research using Map3k14 knockout cell lines suggests that NIK functions upstream of IKK-1 to activate both IRF3 and IRF7, and may be important for an appropriate cellular antiviral response (72).
There are no known human mutations of MAP3K14. However, NF-κB signaling is often activated in and contributes to various human diseases including cancer and inflammatory disorders. Several studies suggest that EGFR receptors, which are often overexpressed on tumor cells, can activate NF-κB pathways that are dependent on NIK (21;22). Additionally, the non-canonical NF-κB pathway is activated by some oncogenic viruses, such as Epstein-Barr virus (EBV) (30) or human T-cell leukemia virus type I (HTLV-I) (73). The bacterium Helicobacter pylori, which has been shown to be the cause of various human gastric diseases, also activates the non-canonical NF-κB pathway by activating NIK (74). The non-canonical NF-κB pathway contributes to the development of inflammatory disorders and autoimmune diseases by being necessary for tertiary lymphoid organ (TLO) development under control of LTβR signaling, and being activated by overexpression of the pro-survival cytokine BAFFR leading to survival of unwanted autoantibody producing B cells (27). TLOs are organized T- and B-cell areas that form at sites of chronic inflammation (75). They are often found in patients suffering from inflammatory disorders such as rheumatoid arthritis, multiple sclerosis, ulcerative colitis, chronic hepatitis C and Sjogren’s syndrome (OMIM %270150), which is an inflammation of exocrine organs. Interestingly, alymphoplasia mice have been suggested to be a model for the latter disease as they exhibit exocrine organ inflammation and a reduced number of Tregs (45;64) (see above). NIK-deficient animals have been shown to be resistant to the induction of rheumatoid arthritis due to a defect in osteoclastogenesis in response to RANK signaling (76), and to experimental autoimmune encephalomyelitis due to the reduction in Th17 cells (67).
Alymphoplasia mice contain a G to R change at amino acid 855 of NIK to produce a protein that retains kinase function, but is defective in IKK-1 and TRAF2 binding. This protein is apparently able to function normally to produce type I IFNs (70). However, the similarity of phenotypes between alymphoplasia mice and Map3k14 knockout animals (3;9), suggests that the IKK-1/TRAF-interacting C-terminal domain of NIK is essential for its role in the non-canonical NF-κB pathway. It is likely that the abnormal protein resulting from the lucky mutation, which would be truncated in the kinase domain, is similarly nonfunctional. Lucky mice appear to have highly similar phenotypes to both alymphoplasia animals and Map3k14 knockout mice (3;9), as they are unable to mount appropriate antibody responses, display defects in B cell maturation and exhibit a lack of secondary lymphoid organs.
Although the lucky mutation results in truncation of the NIK kinase prior to the kinase domain, it is possible that expression of this protein may behave as a dominant-negative due to the retention of the N-terminal domain, which can bind to several proteins including its own C-terminal domain (see Protein Prediction). Overexpression of C-terminally truncated and kinase-dead NIK constructs can prevent NF-κB activation in vitro (2). However, the recessive nature of both the alymphoplasia and lucky mutations suggests that in most contexts these proteins do not behave in a dominant-negative fashion in vivo.
As a MAP3 kinase, NIK may have some overlapping functions with related proteins particularly MAP3K8, which is also known as TPL2 or COT (mutated in Sluggish). TPL2 functions downstream of TLR and TNF-α signaling, and activates the MEK/ERK pathway (77). In some cell lines, NIK is also able to activate the MEK/ERK pathway (15). TPL2 has been shown to interact with and activate NIK in vitro (78), and is upstream of NIK activation of the canonical NF-κB pathway in response to both CD3/CD28 (necessary for full T cell activation) and EBV stimulation (11;79-81). In addition, both kinases are implicated in canonical NF-κB activation in response to CD40 stimulation (82;83).
|Primers||Primers cannot be located by automatic search.|
Lucky genotyping is performed by amplifying the region containing the mutation using PCR, followed by sequencing of the amplified region to detect the single nucleotide change.
Primers for PCR amplification
Lucky(F): 5’- TGAGTGAAAATGTCCCGTGAGCAG -3’
Lucky(R): 5’- TGCATACCAAGGGCAGCAATCAG -3’
1) 94°C 2:00
2) 94°C 0:30
3) 56°C 0:30
4) 72°C 1:00
5) repeat steps (2-4) 29X
6) 72°C 7:00
7) 4°C ∞
Primers for sequencing
Lucky_seq(F): 5’- GCACCAGATCTCATTATACGTGG -3’
Lucky_seq(R): 5’- TCAGGGTCTCACAGCATAGTC -3’
The following sequence of 1140 nucleotides (from Genbank genomic region NC_000077 for linear DNA sequence of Map3k14) is amplified:
29106 tgagt gaaaatgtcc cgtgagcaga ggatgccgtc ctccctctcc ctccctccca
29161 catctccctt ttccttcagt tctctgcctg aataactttg gaacctgaag cgatttgttc
29221 aacttgaggg attgattcta ttcactttta ataacggtgc ttgcccctgt ctcttcaacc
29281 ttggagttac tgagttatat gtcccattat caaggttgtt ggcgactctg cttctcatcg
29341 caggaattat ctgcctaccc caccccccag gcagcctatg gtggccacct ttgccattta
29401 agatttaagt atacagcact ctgcctgcag gccagaagag ggcaccagat ctcattatac
29461 gtggttatga gccaccgcgt ggttgctggg aattgaactc aggcgctcca gaagagcaag
29521 cagtcagtgc tcttaacctc tgaggcatct ccccagcccc acctttgtct tcttattccc
29581 ctaaacccct tttggcctgt cttccttatc atcgcgctgt agggctggta gtctctttag
29641 atgtggtggc catccagcca ccagagccct agctattgac tagagagcct tccccactgc
29701 agtcctctgt ccctctgctg cccaggtcac tggtactgac ctcctcctcc tcctcttcaa
29761 ccccagaaac tcaagccagt ggattatgag tatcgagaag aggtccactg gatgacacac
29821 cagcctcggg tgggcagagg ctccttcggc gaggtccaca gaatgaagga caagcagaca
29881 ggcttccagt gtgctgtcaa aaaggtatgc cgaggtgata caccactggg ctggcaccca
29941 aatttccaac actggggagg ctgaggcagg aggatgacca tggatcctag gccagctggg
30001 actatgctgt gagaccctga cttggaaaaa aaaaattaca tagtaggtag aactctgggg
30061 agctgaaagg gaagccacac aggggctgct gccttccacc tcagctttct gtcagcaaca
30121 gtcatggggt atccggggct ctcccttgat ggttggcacc ctagctgctc tcgggtcagc
30181 tggagctgga agggagccgt ctggtgtgtc acatggcctg gcctgattgc tgcccttggt
PCR primer binding sites are underlined; sequencing primer binding sites are highlighted in gray; the mutated C is shown in red text.
1. Siebenlist, U., Brown, K., and Claudio, E. (2005) Control of Lymphocyte Development by Nuclear Factor-kappaB. Nat. Rev. Immunol. 5, 435-445.
2. Malinin, N. L., Boldin, M. P., Kovalenko, A. V., and Wallach, D. (1997) MAP3K-Related Kinase Involved in NF-kappaB Induction by TNF, CD95 and IL-1. Nature. 385, 540-544.
3. Shinkura, R., Kitada, K., Matsuda, F., Tashiro, K., Ikuta, K., Suzuki, M., Kogishi, K., Serikawa, T., and Honjo, T. (1999) Alymphoplasia is Caused by a Point Mutation in the Mouse Gene Encoding Nf-Kappa b-Inducing Kinase. Nat. Genet. 22, 74-77.
4. Kornev, A. P., Haste, N. M., Taylor, S. S., and Eyck, L. F. (2006) Surface Comparison of Active and Inactive Protein Kinases Identifies a Conserved Activation Mechanism. Proc. Natl. Acad. Sci. U. S. A. 103, 17783-17788.
5. Lin, X., Mu, Y., Cunningham, E. T.,Jr, Marcu, K. B., Geleziunas, R., and Greene, W. C. (1998) Molecular Determinants of NF-kappaB-Inducing Kinase Action. Mol. Cell. Biol. 18, 5899-5907.
6. Regnier, C. H., Song, H. Y., Gao, X., Goeddel, D. V., Cao, Z., and Rothe, M. (1997) Identification and Characterization of an IkappaB Kinase. Cell. 90, 373-383.
7. Ling, L., Cao, Z., and Goeddel, D. V. (1998) NF-kappaB-Inducing Kinase Activates IKK-Alpha by Phosphorylation of Ser-176. Proc. Natl. Acad. Sci. U. S. A. 95, 3792-3797.
8. Xiao, G., Harhaj, E. W., and Sun, S. C. (2001) NF-kappaB-Inducing Kinase Regulates the Processing of NF-kappaB2 p100. Mol. Cell. 7, 401-409.
9. Yin, L., Wu, L., Wesche, H., Arthur, C. D., White, J. M., Goeddel, D. V., and Schreiber, R. D. (2001) Defective Lymphotoxin-Beta Receptor-Induced NF-kappaB Transcriptional Activity in NIK-Deficient Mice. Science. 291, 2162-2165.
10. Jiang, X., Takahashi, N., Matsui, N., Tetsuka, T., and Okamoto, T. (2003) The NF-Kappa B Activation in Lymphotoxin Beta Receptor Signaling Depends on the Phosphorylation of p65 at Serine 536. J. Biol. Chem. 278, 919-926.
11. Sanchez-Valdepenas, C., Martin, A. G., Ramakrishnan, P., Wallach, D., and Fresno, M. (2006) NF-kappaB-Inducing Kinase is Involved in the Activation of the CD28 Responsive Element through Phosphorylation of c-Rel and Regulation of its Transactivating Activity. J. Immunol. 176, 4666-4674.
12. Pan, Q., Kravchenko, V., Katz, A., Huang, S., Ii, M., Mathison, J. C., Kobayashi, K., Flavell, R. A., Schreiber, R. D., Goeddel, D., and Ulevitch, R. J. (2006) NF-Kappa B-Inducing Kinase Regulates Selected Gene Expression in the Nod2 Signaling Pathway. Infect. Immun. 74, 2121-2127.
13. Azim, A. C., Wang, X., Park, G. Y., Sadikot, R. T., Cao, H., Mathew, B., Atchison, M., van Breemen, R. B., Joo, M., and Christman, J. W. (2007) NF-kappaB-Inducing Kinase Regulates Cyclooxygenase 2 Gene Expression in Macrophages by Phosphorylation of PU.1. J. Immunol. 179, 7868-7875.
14. Lee, E. J., Seo, S. R., Um, J. W., Park, J., Oh, Y., and Chung, K. C. (2008) NF-kappaB-Inducing Kinase Phosphorylates and Blocks the Degradation of Down Syndrome Candidate Region 1. J. Biol. Chem. 283, 3392-3400.
15. Foehr, E. D., Bohuslav, J., Chen, L. F., DeNoronha, C., Geleziunas, R., Lin, X., O'Mahony, A., and Greene, W. C. (2000) The NF-Kappa B-Inducing Kinase Induces PC12 Cell Differentiation and Prevents Apoptosis. J. Biol. Chem. 275, 34021-34024.
16. Dhawan, P., and Richmond, A. (2002) A Novel NF-Kappa B-Inducing Kinase-MAPK Signaling Pathway Up-Regulates NF-Kappa B Activity in Melanoma Cells. J. Biol. Chem. 277, 7920-7928.
17. Song, H. Y., Regnier, C. H., Kirschning, C. J., Goeddel, D. V., and Rothe, M. (1997) Tumor Necrosis Factor (TNF)-Mediated Kinase Cascades: Bifurcation of Nuclear Factor-kappaB and c-Jun N-Terminal Kinase (JNK/SAPK) Pathways at TNF Receptor-Associated Factor 2. Proc. Natl. Acad. Sci. U. S. A. 94, 9792-9796.
18. Liao, G., Zhang, M., Harhaj, E. W., and Sun, S. C. (2004) Regulation of the NF-kappaB-Inducing Kinase by Tumor Necrosis Factor Receptor-Associated Factor 3-Induced Degradation. J. Biol. Chem. 279, 26243-26250.
19. Hu, W. H., Pendergast, J. S., Mo, X. M., Brambilla, R., Bracchi-Ricard, V., Li, F., Walters, W. M., Blits, B., He, L., Schaal, S. M., and Bethea, J. R. (2005) NIBP, a Novel NIK and IKK(Beta)-Binding Protein that Enhances NF-(Kappa)B Activation. J. Biol. Chem. 280, 29233-29241.
20. Hu, W. H., Mo, X. M., Walters, W. M., Brambilla, R., and Bethea, J. R. (2004) TNAP, a Novel Repressor of NF-kappaB-Inducing Kinase, Suppresses NF-kappaB Activation. J. Biol. Chem. 279, 35975-35983.
21. Habib, A. A., Chatterjee, S., Park, S. K., Ratan, R. R., Lefebvre, S., and Vartanian, T. (2001) The Epidermal Growth Factor Receptor Engages Receptor Interacting Protein and Nuclear Factor-Kappa B (NF-Kappa B)-Inducing Kinase to Activate NF-Kappa B. Identification of a Novel Receptor-Tyrosine Kinase Signalosome. J. Biol. Chem. 276, 8865-8874.
22. Chen, D., Xu, L. G., Chen, L., Li, L., Zhai, Z., and Shu, H. B. (2003) NIK is a Component of the EGF/heregulin Receptor Signaling Complexes. Oncogene. 22, 4348-4355.
23. Xiao, G., and Sun, S. C. (2000) Negative Regulation of the Nuclear Factor Kappa B-Inducing Kinase by a Cis-Acting Domain. J. Biol. Chem. 275, 21081-21085.
24. Birbach, A., Gold, P., Binder, B. R., Hofer, E., de Martin, R., and Schmid, J. A. (2002) Signaling Molecules of the NF-Kappa B Pathway Shuttle Constitutively between Cytoplasm and Nucleus. J. Biol. Chem. 277, 10842-10851.
25. Birbach, A., Bailey, S. T., Ghosh, S., and Schmid, J. A. (2004) Cytosolic, Nuclear and Nucleolar Localization Signals Determine Subcellular Distribution and Activity of the NF-kappaB Inducing Kinase NIK. J. Cell. Sci. 117, 3615-3624.
26. Fagarasan, S., Shinkura, R., Kamata, T., Nogaki, F., Ikuta, K., Tashiro, K., and Honjo, T. (2000) Alymphoplasia (Aly)-Type Nuclear Factor kappaB-Inducing Kinase (NIK) Causes Defects in Secondary Lymphoid Tissue Chemokine Receptor Signaling and Homing of Peritoneal Cells to the Gut-Associated Lymphatic Tissue System. J. Exp. Med. 191, 1477-1486.
27. Dejardin, E. (2006) The Alternative NF-kappaB Pathway from Biochemistry to Biology: Pitfalls and Promises for Future Drug Development. Biochem. Pharmacol. 72, 1161-1179.
28. Park, G. Y., Wang, X., Hu, N., Pedchenko, T. V., Blackwell, T. S., and Christman, J. W. (2006) NIK is Involved in Nucleosomal Regulation by Enhancing Histone H3 Phosphorylation by IKKalpha. J. Biol. Chem. 281, 18684-18690.
29. Dejardin, E., Droin, N. M., Delhase, M., Haas, E., Cao, Y., Makris, C., Li, Z. W., Karin, M., Ware, C. F., and Green, D. R. (2002) The Lymphotoxin-Beta Receptor Induces Different Patterns of Gene Expression Via Two NF-kappaB Pathways. Immunity. 17, 525-535.
30. Luftig, M. A., Cahir-McFarland, E., Mosialos, G., and Kieff, E. (2001) Effects of the NIK Aly Mutation on NF-kappaB Activation by the Epstein-Barr Virus Latent Infection Membrane Protein, Lymphotoxin Beta Receptor, and CD40. J. Biol. Chem. 276, 14602-14606.
31. Smith, C., Andreakos, E., Crawley, J. B., Brennan, F. M., Feldmann, M., and Foxwell, B. M. (2001) NF-kappaB-Inducing Kinase is Dispensable for Activation of NF-kappaB in Inflammatory Settings but Essential for Lymphotoxin Beta Receptor Activation of NF-kappaB in Primary Human Fibroblasts. J. Immunol. 167, 5895-5903.
32. Claudio, E., Brown, K., Park, S., Wang, H., and Siebenlist, U. (2002) BAFF-Induced NEMO-Independent Processing of NF-Kappa B2 in Maturing B Cells. Nat. Immunol. 3, 958-965.
33. Kayagaki, N., Yan, M., Seshasayee, D., Wang, H., Lee, W., French, D. M., Grewal, I. S., Cochran, A. G., Gordon, N. C., Yin, J., Starovasnik, M. A., and Dixit, V. M. (2002) BAFF/BLyS Receptor 3 Binds the B Cell Survival Factor BAFF Ligand through a Discrete Surface Loop and Promotes Processing of NF-kappaB2. Immunity. 17, 515-524.
34. Coope, H. J., Atkinson, P. G., Huhse, B., Belich, M., Janzen, J., Holman, M. J., Klaus, G. G., Johnston, L. H., and Ley, S. C. (2002) CD40 Regulates the Processing of NF-kappaB2 p100 to p52. EMBO J. 21, 5375-5385.
35. Novack, D. V., Yin, L., Hagen-Stapleton, A., Schreiber, R. D., Goeddel, D. V., Ross, F. P., and Teitelbaum, S. L. (2003) The IkappaB Function of NF-kappaB2 p100 Controls Stimulated Osteoclastogenesis. J. Exp. Med. 198, 771-781.
36. Vallabhapurapu, S., Matsuzawa, A., Zhang, W., Tseng, P. H., Keats, J. J., Wang, H., Vignali, D. A., Bergsagel, P. L., and Karin, M. (2008) Nonredundant and Complementary Functions of TRAF2 and TRAF3 in a Ubiquitination Cascade that Activates NIK-Dependent Alternative NF-kappaB Signaling. Nat. Immunol. 9, 1364-1370.
37. Zarnegar, B. J., Wang, Y., Mahoney, D. J., Dempsey, P. W., Cheung, H. H., He, J., Shiba, T., Yang, X., Yeh, W. C., Mak, T. W., Korneluk, R. G., and Cheng, G. (2008) Noncanonical NF-kappaB Activation Requires Coordinated Assembly of a Regulatory Complex of the Adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the Kinase NIK. Nat. Immunol. 9, 1371-1378.
38. Gardam, S., Sierro, F., Basten, A., Mackay, F., and Brink, R. (2008) TRAF2 and TRAF3 Signal Adapters Act Cooperatively to Control the Maturation and Survival Signals Delivered to B Cells by the BAFF Receptor. Immunity. 28, 391-401.
39. Qing, G., and Xiao, G. (2005) Essential Role of IkappaB Kinase Alpha in the Constitutive Processing of NF-kappaB2 p100. J. Biol. Chem. 280, 9765-9768.
40. Xiao, G., Fong, A., and Sun, S. C. (2004) Induction of p100 Processing by NF-kappaB-Inducing Kinase Involves Docking IkappaB Kinase Alpha (IKKalpha) to p100 and IKKalpha-Mediated Phosphorylation. J. Biol. Chem. 279, 30099-30105.
41. Fong, A., and Sun, S. C. (2002) Genetic Evidence for the Essential Role of Beta-Transducin Repeat-Containing Protein in the Inducible Processing of NF-Kappa B2/p100. J. Biol. Chem. 277, 22111-22114.
42. Miyawaki, S., Nakamura, Y., Suzuka, H., Koba, M., Yasumizu, R., Ikehara, S., and Shibata, Y. (1994) A New Mutation, Aly, that Induces a Generalized Lack of Lymph Nodes Accompanied by Immunodeficiency in Mice. Eur. J. Immunol. 24, 429-434.
43. Koike, R., Nishimura, T., Yasumizu, R., Tanaka, H., Hataba, Y., Hataba, Y., Watanabe, T., Miyawaki, S., and Miyasaka, M. (1996) The Splenic Marginal Zone is Absent in Alymphoplastic Aly Mutant Mice. Eur. J. Immunol. 26, 669-675.
44. Shinkura, R., Matsuda, F., Sakiyama, T., Tsubata, T., Hiai, H., Paumen, M., Miyawaki, S., and Honjo, T. (1996) Defects of Somatic Hypermutation and Class Switching in Alymphoplasia (Aly) Mutant Mice. Int. Immunol. 8, 1067-1075.
45. Tsubata, R., Tsubata, T., Hiai, H., Shinkura, R., Matsumura, R., Sumida, T., Miyawaki, S., Ishida, H., Kumagai, S., Nakao, K., and Honjo, T. (1996) Autoimmune Disease of Exocrine Organs in Immunodeficient Alymphoplasia Mice: A Spontaneous Model for Sjogren's Syndrome. Eur. J. Immunol. 26, 2742-2748.
46. Yasumizu, R., Miyawaki, S., Koba, M., Kondoh-Tanaka, M., Amoh, Y., Nishio, N., Yamamoto, Y., Watanabe, H., and Ikehara, S. (2000) Pathology of ALY Mice: Congenital Immunodeficiency with Lymph Node and Peyer's Patch Defects. Immunobiology. 202, 213-225.
47. Nishimura, T., Koike, R., and Miyasaka, M. (2000) Mammary Glands of Aly Mice: Developmental Changes and Lactation-Related Expression of Specific Proteins, Alpha-Casein, GLyCAM-1 and MAdCAM-1. Am. J. Reprod. Immunol. 43, 351-358.
48. Caamano, J. H., Rizzo, C. A., Durham, S. K., Barton, D. S., Raventos-Suarez, C., Snapper, C. M., and Bravo, R. (1998) Nuclear Factor (NF)-Kappa B2 (p100/p52) is Required for Normal Splenic Microarchitecture and B Cell-Mediated Immune Responses. J. Exp. Med. 187, 185-196.
49. Franzoso, G., Carlson, L., Poljak, L., Shores, E. W., Epstein, S., Leonardi, A., Grinberg, A., Tran, T., Scharton-Kersten, T., Anver, M., Love, P., Brown, K., and Siebenlist, U. (1998) Mice Deficient in Nuclear Factor (NF)-Kappa B/p52 Present with Defects in Humoral Responses, Germinal Center Reactions, and Splenic Microarchitecture. J. Exp. Med. 187, 147-159.
50. Weih, F., Carrasco, D., Durham, S. K., Barton, D. S., Rizzo, C. A., Ryseck, R. P., Lira, S. A., and Bravo, R. (1995) Multiorgan Inflammation and Hematopoietic Abnormalities in Mice with a Targeted Disruption of RelB, a Member of the NF-Kappa B/Rel Family. Cell. 80, 331-340.
51. Yilmaz, Z. B., Weih, D. S., Sivakumar, V., and Weih, F. (2003) RelB is Required for Peyer's Patch Development: Differential Regulation of p52-RelB by Lymphotoxin and TNF. EMBO J. 22, 121-130.
52. Senftleben, U., Cao, Y., Xiao, G., Greten, F. R., Krahn, G., Bonizzi, G., Chen, Y., Hu, Y., Fong, A., Sun, S. C., and Karin, M. (2001) Activation by IKKalpha of a Second, Evolutionary Conserved, NF-Kappa B Signaling Pathway. Science. 293, 1495-1499.
53. Drayton, D. L., Bonizzi, G., Ying, X., Liao, S., Karin, M., and Ruddle, N. H. (2004) I Kappa B Kinase Complex Alpha Kinase Activity Controls Chemokine and High Endothelial Venule Gene Expression in Lymph Nodes and Nasal-Associated Lymphoid Tissue. J. Immunol. 173, 6161-6168.
54. Futterer, A., Mink, K., Luz, A., Kosco-Vilbois, M. H., and Pfeffer, K. (1998) The Lymphotoxin Beta Receptor Controls Organogenesis and Affinity Maturation in Peripheral Lymphoid Tissues. Immunity. 9, 59-70.
55. Sasaki, Y., Casola, S., Kutok, J. L., Rajewsky, K., and Schmidt-Supprian, M. (2004) TNF Family Member B Cell-Activating Factor (BAFF) Receptor-Dependent and -Independent Roles for BAFF in B Cell Physiology. J. Immunol. 173, 2245-2252.
56. Shulga-Morskaya, S., Dobles, M., Walsh, M. E., Ng, L. G., MacKay, F., Rao, S. P., Kalled, S. L., and Scott, M. L. (2004) B Cell-Activating Factor Belonging to the TNF Family Acts through Separate Receptors to Support B Cell Survival and T Cell-Independent Antibody Formation. J. Immunol. 173, 2331-2341.
57. Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., Armstrong, A., Shen, V., Bain, S., Cosman, D., Anderson, D., Morrissey, P. J., Peschon, J. J., and Schuh, J. (1999) RANK is Essential for Osteoclast and Lymph Node Development. Genes Dev. 13, 2412-2424.
58. Kong, Y. Y., Yoshida, H., Sarosi, I., Tan, H. L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C. R., Lacey, D. L., Mak, T. W., Boyle, W. J., and Penninger, J. M. (1999) OPGL is a Key Regulator of Osteoclastogenesis, Lymphocyte Development and Lymph-Node Organogenesis. Nature. 397, 315-323.
59. Weih, D. S., Yilmaz, Z. B., and Weih, F. (2001) Essential Role of RelB in Germinal Center and Marginal Zone Formation and Proper Expression of Homing Chemokines. J. Immunol. 167, 1909-1919.
60. Yamada, T., Mitani, T., Yorita, K., Uchida, D., Matsushima, A., Iwamasa, K., Fujita, S., and Matsumoto, M. (2000) Abnormal Immune Function of Hemopoietic Cells from Alymphoplasia (Aly) Mice, a Natural Strain with Mutant NF-Kappa B-Inducing Kinase. J. Immunol. 165, 804-812.
61. Matsushima, A., Kaisho, T., Rennert, P. D., Nakano, H., Kurosawa, K., Uchida, D., Takeda, K., Akira, S., and Matsumoto, M. (2001) Essential Role of Nuclear Factor (NF)-kappaB-Inducing Kinase and Inhibitor of kappaB (IkappaB) Kinase Alpha in NF-kappaB Activation through Lymphotoxin Beta Receptor, but Not through Tumor Necrosis Factor Receptor I. J. Exp. Med. 193, 631-636.
62. Boehm, T., Scheu, S., Pfeffer, K., and Bleul, C. C. (2003) Thymic Medullary Epithelial Cell Differentiation, Thymocyte Emigration, and the Control of Autoimmunity Require Lympho-Epithelial Cross Talk Via LTbetaR. J. Exp. Med. 198, 757-769.
63. Kinoshita, D., Hirota, F., Kaisho, T., Kasai, M., Izumi, K., Bando, Y., Mouri, Y., Matsushima, A., Niki, S., Han, H., Oshikawa, K., Kuroda, N., Maegawa, M., Irahara, M., Takeda, K., Akira, S., and Matsumoto, M. (2006) Essential Role of IkappaB Kinase Alpha in Thymic Organogenesis Required for the Establishment of Self-Tolerance. J. Immunol. 176, 3995-4002.
64. Tamura, C., Nakazawa, M., Kasahara, M., Hotta, C., Yoshinari, M., Sato, F., and Minami, M. (2006) Impaired Function of Dendritic Cells in Alymphoplasia (aly/aly) Mice for Expansion of CD25+CD4+ Regulatory T Cells. Autoimmunity. 39, 445-453.
65. De Trez, C., Schneider, K., Potter, K., Droin, N., Fulton, J., Norris, P. S., Ha, S. W., Fu, Y. X., Murphy, T., Murphy, K. M., Pfeffer, K., Benedict, C. A., and Ware, C. F. (2008) The Inhibitory HVEM-BTLA Pathway Counter Regulates Lymphotoxin Receptor Signaling to Achieve Homeostasis of Dendritic Cells. J. Immunol. 180, 238-248.
66. Lind, E. F., Ahonen, C. L., Wasiuk, A., Kosaka, Y., Becher, B., Bennett, K. A., and Noelle, R. J. (2008) Dendritic Cells Require the NF-kappaB2 Pathway for Cross-Presentation of Soluble Antigens. J. Immunol. 181, 354-363.
67. Jin, W., Zhou, X. F., Yu, J., Cheng, X., and Sun, S. C. (2009) Regulation of Th17 Cell Differentiation and EAE Induction by MAP3K NIK. Blood. 113, 6603-6610.
68. Kaisho, T., Takeda, K., Tsujimura, T., Kawai, T., Nomura, F., Terada, N., and Akira, S. (2001) IkappaB Kinase Alpha is Essential for Mature B Cell Development and Function. J. Exp. Med. 193, 417-426.
69. Elgueta, R., Benson, M. J., de Vries, V. C., Wasiuk, A., Guo, Y., and Noelle, R. J. (2009) Molecular Mechanism and Function of CD40/CD40L Engagement in the Immune System. Immunol. Rev. 229, 152-172.
70. Hoshino, K., Sugiyama, T., Matsumoto, M., Tanaka, T., Saito, M., Hemmi, H., Ohara, O., Akira, S., and Kaisho, T. (2006) IkappaB Kinase-Alpha is Critical for Interferon-Alpha Production Induced by Toll-Like Receptors 7 and 9. Nature. 440, 949-953.
71. Kaisho, T. (2008) Type I Interferon Production by Nucleic Acid-Stimulated Dendritic Cells. Front. Biosci. 13, 6034-6042.
72. Wang, R. P., Zhang, M., Li, Y., Diao, F. C., Chen, D., Zhai, Z., and Shu, H. B. (2008) Differential Regulation of IKK Alpha-Mediated Activation of IRF3/7 by NIK. Mol. Immunol. 45, 1926-1934.
73. Qu, Z., Qing, G., Rabson, A., and Xiao, G. (2004) Tax Deregulation of NF-kappaB2 p100 Processing Involves both Beta-TrCP-Dependent and -Independent Mechanisms. J. Biol. Chem. 279, 44563-44572.
74. Neumann, M., Foryst-Ludwig, A., Klar, S., Schweitzer, K., and Naumann, M. (2006) The PAK1 Autoregulatory Domain is Required for Interaction with NIK in Helicobacter Pylori-Induced NF-kappaB Activation. Biol. Chem. 387, 79-86.
75. Aloisi, F., and Pujol-Borrell, R. (2006) Lymphoid Neogenesis in Chronic Inflammatory Diseases. Nat. Rev. Immunol. 6, 205-217.
76. Aya, K., Alhawagri, M., Hagen-Stapleton, A., Kitaura, H., Kanagawa, O., and Novack, D. V. (2005) NF-(Kappa)B-Inducing Kinase Controls Lymphocyte and Osteoclast Activities in Inflammatory Arthritis. J. Clin. Invest. 115, 1848-1854.
77. Banerjee, A., and Gerondakis, S. (2007) Coordinating TLR-Activated Signaling Pathways in Cells of the Immune System. Immunol. Cell Biol. 85, 420-424.
78.Lin, X., Cunningham, E. T.,Jr., Mu, Y., Geleziunas, R., and Greene, W. C. (1999) The Proto-Oncogene Cot Kinase Participates in CD3/CD28 Induction of NF-kappaB Acting through the NF-kappaB-Inducing Kinase and IkappaB Kinases. Immunity. 10, 271-280.
79. Eliopoulos, A. G., Davies, C., Blake, S. S., Murray, P., Najafipour, S., Tsichlis, P. N., and Young, L. S. (2002) The Oncogenic Protein Kinase Tpl-2/Cot Contributes to Epstein-Barr Virus-Encoded Latent Infection Membrane Protein 1-Induced NF-kappaB Signaling Downstream of TRAF2. J. Virol. 76, 4567-4579.
80. Sanchez-Valdepenas, C., Punzon, C., San-Antonio, B., Martin, A. G., and Fresno, M. (2007) Differential Regulation of p65 and c-Rel NF-kappaB Transactivating Activity by Cot, Protein Kinase C Zeta and NIK Protein Kinases in CD3/CD28 Activated T Cells. Cell. Signal. 19, 528-537.
81. Wittwer, T., and Schmitz, M. L. (2008) NIK and Cot Cooperate to Trigger NF-kappaB p65 Phosphorylation. Biochem. Biophys. Res. Commun. 371, 294-297.
82. Ramakrishnan, P., Wang, W., and Wallach, D. (2004) Receptor-Specific Signaling for both the Alternative and the Canonical NF-kappaB Activation Pathways by NF-kappaB-Inducing Kinase. Immunity. 21, 477-489.
|Science Writers||Nora G. Smart|
|Illustrators||Diantha La Vine|
|Authors||Carrie N. Arnold, Bruce Beutler|
|List [record 1 of 1]|